In the last 12 months, insiders at ANI PHARMACEUTICALS INC ($ANIP) filed 386 transactions with the SEC: 0 open-market purchases totaling $0 and 174 sales totaling $130,721,840. Net insider sentiment: net selling.
ANI PHARMACEUTICALS INC operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) — 76 transactions totaling $64,405,047
- Lalwani Nikhil (PRESIDENT & CEO) — 36 transactions totaling $36,260,038
- Gassert Chad (SVP - CORP. DEV. & STRATEGY) — 25 transactions totaling $16,856,279
- CAREY STEPHEN P. (SVP & CFO) — 32 transactions totaling $15,050,218
- MERIDIAN VENTURE PARTNERS II LP (TenPercentOwner) — 1 transaction totaling $11,700,000
View all SEC Filings for ANI PHARMACEUTICALS INC (ANIP).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | S | Common Stock | 4772 | $74.91 | 38,730.0000 | 23,076,000 | 10.97% | 0.02% |
| March 13, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 3162 | $71.64 | 91,309.0000 | 23,076,000 | 3.35% | 0.01% |
| March 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 500 | $72.62 | 79,390.0000 | 23,076,000 | 0.63% | 0.00% |
| March 6, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 1485 | $75.00 | 57,033.0000 | 23,076,000 | 2.54% | 0.01% |
| March 7, 2026 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 3314 | $74.04 | 81,468.0000 | 23,076,000 | 3.91% | 0.01% |
| March 7, 2026 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 17060 | $74.04 | 404,889.0000 | 23,076,000 | 4.04% | 0.07% |
| March 9, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 3602 | $74.18 | 94,471.0000 | 23,076,000 | 3.67% | 0.02% |
| March 6, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 2121 | $74.22 | 101,387.0000 | 23,076,000 | 2.05% | 0.01% |
| March 7, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 3314 | $74.04 | 98,073.0000 | 23,076,000 | 3.27% | 0.01% |
| March 7, 2026 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 5150 | $74.04 | 180,393.0000 | 23,076,000 | 2.78% | 0.02% |
| March 9, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 5087 | $74.13 | 51,946.0000 | 23,076,000 | 8.92% | 0.02% |
| March 5, 2026 | CAREY STEPHEN P. | SVP & CFO | S | Common Stock | 3312 | $75.42 | 189,543.0000 | 23,076,000 | 1.72% | 0.01% |
| March 5, 2026 | CAREY STEPHEN P. | SVP & CFO | M | Stock Option (right to buy) | 3312 | $49.51 | 9,938.0000 | 23,076,000 | 25.00% | 0.01% |
| March 5, 2026 | CAREY STEPHEN P. | SVP & CFO | S | Common Stock | 4000 | $75.56 | 185,543.0000 | 23,076,000 | 2.11% | 0.02% |
| March 5, 2026 | CAREY STEPHEN P. | SVP & CFO | M | Common Stock | 3312 | $49.51 | 192,855.0000 | 23,076,000 | 1.75% | 0.01% |
| March 2, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 417 | $74.00 | 103,508.0000 | 23,076,000 | 0.40% | 0.00% |
| March 3, 2026 | Gutwerg Ori | SVP, GENERICS | S | Common Stock | 2060 | $76.50 | 84,782.0000 | 23,076,000 | 2.37% | 0.01% |
| March 3, 2026 | Walsh Patrick D | Director | S | Common Stock | 6000 | $74.23 | 52,405.0000 | 23,076,000 | 10.27% | 0.03% |
| Feb. 26, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | A | Common Stock | 6021 | $77.15 | 44,130.0000 | 23,076,000 | 15.80% | 0.03% |
| Feb. 28, 2026 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 2773 | $73.90 | 189,543.0000 | 23,076,000 | 1.44% | 0.01% |
| Feb. 26, 2026 | CAREY STEPHEN P. | SVP & CFO | A | Common Stock | 22233 | $77.15 | 192,316.0000 | 23,076,000 | 13.07% | 0.10% |
| Feb. 28, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 1555 | $73.90 | 79,890.0000 | 23,076,000 | 1.91% | 0.01% |
| Feb. 26, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | A | Common Stock | 13895 | $77.15 | 81,445.0000 | 23,076,000 | 20.57% | 0.06% |
| Feb. 28, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 1555 | $73.90 | 58,518.0000 | 23,076,000 | 2.59% | 0.01% |
| Feb. 26, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | A | Common Stock | 10810 | $77.15 | 60,073.0000 | 23,076,000 | 21.94% | 0.05% |
| Feb. 28, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | F | Common Stock | 2221 | $73.90 | 233,406.0000 | 23,076,000 | 0.94% | 0.01% |
| Feb. 26, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | A | Common Stock | 11116 | $77.15 | 235,627.0000 | 23,076,000 | 4.95% | 0.05% |
| Feb. 28, 2026 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 2221 | $73.90 | 86,842.0000 | 23,076,000 | 2.49% | 0.01% |
| Feb. 26, 2026 | Gutwerg Ori | SVP, GENERICS | A | Common Stock | 12969 | $77.15 | 89,063.0000 | 23,076,000 | 17.04% | 0.06% |
| Feb. 28, 2026 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 12217 | $73.90 | 421,949.0000 | 23,076,000 | 2.81% | 0.05% |
| Feb. 26, 2026 | Lalwani Nikhil | PRESIDENT & CEO | A | Common Stock | 75592 | $77.15 | 434,166.0000 | 23,076,000 | 21.08% | 0.33% |
| Feb. 28, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 2221 | $73.90 | 103,925.0000 | 23,076,000 | 2.09% | 0.01% |
| Feb. 26, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | A | Common Stock | 21306 | $77.15 | 106,146.0000 | 23,076,000 | 25.11% | 0.09% |
| Feb. 28, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F | Common Stock | 628 | $73.90 | 43,502.0000 | 23,076,000 | 1.42% | 0.00% |
| Feb. 26, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | A | Common Stock | 11116 | $77.15 | 537,976.0000 | 23,076,000 | 2.11% | 0.05% |
| Feb. 20, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 1730 | $77.99 | 49,263.0000 | 23,076,000 | 3.39% | 0.01% |
| Feb. 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 5323 | $78.02 | 84,840.0000 | 23,076,000 | 5.90% | 0.02% |
| Feb. 19, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 2084 | $77.53 | 50,993.0000 | 23,076,000 | 3.93% | 0.01% |
| Feb. 14, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 1290 | $77.36 | 53,077.0000 | 23,076,000 | 2.37% | 0.01% |
| Feb. 12, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 3173 | $76.70 | 99,598.0000 | 23,076,000 | 3.09% | 0.01% |
| Feb. 12, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 7032 | $76.55 | 92,566.0000 | 23,076,000 | 7.06% | 0.03% |
| Feb. 14, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 2403 | $77.36 | 90,163.0000 | 23,076,000 | 2.60% | 0.01% |
| Feb. 12, 2026 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 11688 | $76.70 | 368,872.0000 | 23,076,000 | 3.07% | 0.05% |
| Feb. 14, 2026 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 10298 | $77.36 | 358,574.0000 | 23,076,000 | 2.79% | 0.04% |
| Feb. 12, 2026 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 1775 | $76.70 | 77,982.0000 | 23,076,000 | 2.23% | 0.01% |
| Feb. 14, 2026 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 1888 | $77.36 | 76,094.0000 | 23,076,000 | 2.42% | 0.01% |
| Feb. 12, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | F | Common Stock | 1608 | $76.70 | 226,228.0000 | 23,076,000 | 0.71% | 0.01% |
| Feb. 14, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | F | Common Stock | 1717 | $77.36 | 224,511.0000 | 23,076,000 | 0.76% | 0.01% |
| Feb. 12, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 1180 | $76.70 | 54,367.0000 | 23,076,000 | 2.12% | 0.01% |
| Feb. 12, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 1534 | $76.70 | 69,829.0000 | 23,076,000 | 2.15% | 0.01% |
| Feb. 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 500 | $76.80 | 69,329.0000 | 23,076,000 | 0.72% | 0.00% |
| Feb. 14, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 1779 | $77.36 | 67,550.0000 | 23,076,000 | 2.57% | 0.01% |
| Feb. 12, 2026 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 2829 | $76.70 | 172,531.0000 | 23,076,000 | 1.61% | 0.01% |
| Feb. 14, 2026 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 2448 | $77.36 | 170,083.0000 | 23,076,000 | 1.42% | 0.01% |
| Feb. 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F | Common Stock | 566 | $76.70 | 38,594.0000 | 23,076,000 | 1.45% | 0.00% |
| Feb. 14, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F | Common Stock | 485 | $77.36 | 38,109.0000 | 23,076,000 | 1.26% | 0.00% |
| Feb. 11, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | F | Common Stock | 4269 | $76.25 | 227,836.0000 | 23,076,000 | 1.84% | 0.02% |
| Feb. 11, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 3011 | $76.25 | 71,363.0000 | 23,076,000 | 4.05% | 0.01% |
| Feb. 11, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 3017 | $76.25 | 55,547.0000 | 23,076,000 | 5.15% | 0.01% |
| Feb. 11, 2026 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 5503 | $76.25 | 175,360.0000 | 23,076,000 | 3.04% | 0.02% |
| Feb. 11, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | F | Common Stock | 2898 | $76.25 | 526,860.0000 | 23,076,000 | 0.55% | 0.01% |
| Feb. 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F | Common Stock | 1762 | $76.25 | 39,160.0000 | 23,076,000 | 4.31% | 0.01% |
| Feb. 11, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 4546 | $76.25 | 102,771.0000 | 23,076,000 | 4.24% | 0.02% |
| Feb. 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 30659 | $76.25 | 380,560.0000 | 23,076,000 | 7.46% | 0.13% |
| Feb. 11, 2026 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 4267 | $76.25 | 79,757.0000 | 23,076,000 | 5.08% | 0.02% |
| Jan. 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 500 | $84.33 | 74,374.0000 | 23,076,000 | 0.67% | 0.00% |
| Dec. 18, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 1622 | $82.40 | 58,564.0000 | 23,076,000 | 2.69% | 0.01% |
| Dec. 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $82.32 | 74,874.0000 | 23,076,000 | 0.53% | 0.00% |
| Dec. 5, 2025 | TANNENBAUM RENEE P | Director | S | Common Stock | 1800 | $81.15 | 25,157.0000 | 23,076,000 | 6.68% | 0.01% |
| Nov. 13, 2025 | Walsh Patrick D | Director | G | Common Stock | 3000 | $0.00 | 58,405.0000 | 23,076,000 | 4.89% | 0.01% |
| Nov. 13, 2025 | Walsh Patrick D | Director | S | Common Stock | 8643 | $86.88 | 61,405.0000 | 23,076,000 | 12.34% | 0.04% |
| Nov. 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $87.27 | 75,274.0000 | 23,076,000 | 0.53% | 0.00% |
| Nov. 13, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 94 | $88.00 | 232,105.0000 | 23,076,000 | 0.04% | 0.00% |
| Nov. 12, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 14642 | $89.07 | 232,199.0000 | 23,076,000 | 5.93% | 0.06% |
| Oct. 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $90.09 | 75,674.0000 | 23,076,000 | 0.53% | 0.00% |
| Sept. 19, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 1000 | $98.04 | 60,186.0000 | 22,322,000 | 1.63% | 0.00% |
| Sept. 12, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 1710 | $97.71 | 61,186.0000 | 22,322,000 | 2.72% | 0.01% |
| Sept. 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $98.42 | 76,074.0000 | 22,322,000 | 0.52% | 0.00% |
| Sept. 3, 2025 | Pera Antonio R | Director | S | Common Stock | 7292 | $94.94 | 22,660.0000 | 22,322,000 | 24.35% | 0.03% |
| Aug. 25, 2025 | Leonard Matthew J | Director | S | Common Stock | 2528 | $90.62 | 6,864.0000 | 22,322,000 | 26.92% | 0.01% |
| Aug. 22, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 1763 | $91.10 | 62,896.0000 | 22,322,000 | 2.73% | 0.01% |
| Aug. 21, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 52988 | $90.44 | 529,508.0000 | 22,322,000 | 9.10% | 0.24% |
| Aug. 20, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 47012 | $90.27 | 582,496.0000 | 22,322,000 | 7.47% | 0.21% |
| Aug. 20, 2025 | Pera Antonio R | Director | S | Common Stock | 5421 | $89.73 | 29,952.0000 | 22,322,000 | 15.33% | 0.02% |
| Aug. 18, 2025 | Thoma Jeanne | Director | S | Common Stock | 14675 | $88.87 | 23,405.0000 | 22,322,000 | 38.54% | 0.07% |
| Aug. 18, 2025 | Thoma Jeanne | Director | S | Common Stock | 6865 | $89.76 | 38,080.0000 | 22,322,000 | 15.27% | 0.03% |
| Aug. 15, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 52990 | $87.15 | 629,508.0000 | 22,322,000 | 7.76% | 0.24% |
| Aug. 15, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $86.97 | 246,841.0000 | 22,322,000 | 7.50% | 0.09% |
| Aug. 15, 2025 | Walsh Patrick D | Director | S | Common Stock | 9000 | $89.05 | 70,048.0000 | 22,322,000 | 11.39% | 0.04% |
| Aug. 18, 2025 | Leonard Matthew J | Director | S | Common Stock | 6937 | $88.17 | 9,392.0000 | 22,322,000 | 42.48% | 0.03% |
| Aug. 14, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 47010 | $89.48 | 682,498.0000 | 22,322,000 | 6.44% | 0.21% |
| Aug. 12, 2025 | Lalwani Nikhil | PRESIDENT & CEO | S | Common Stock | 56960 | $85.93 | 411,219.0000 | 22,322,000 | 12.17% | 0.26% |
| Aug. 12, 2025 | HAUGHEY THOMAS | Director | S | Common Stock | 19341 | $85.93 | 36,521.0000 | 22,322,000 | 34.62% | 0.09% |
| Aug. 12, 2025 | CAREY STEPHEN P. | SVP & CFO | M | Stock Option (right to buy) | 50000 | $46.49 | 0.0000 | 22,322,000 | 100.00% | 0.22% |
| Aug. 12, 2025 | CAREY STEPHEN P. | SVP & CFO | S | Common Stock | 50000 | $86.07 | 180,863.0000 | 22,322,000 | 21.66% | 0.22% |
| Aug. 12, 2025 | CAREY STEPHEN P. | SVP & CFO | M | Common Stock | 50000 | $46.49 | 230,863.0000 | 22,322,000 | 27.65% | 0.22% |
| Aug. 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $88.87 | 76,474.0000 | 22,322,000 | 0.52% | 0.00% |
| Aug. 12, 2025 | Gutwerg Ori | SVP, GENERICS | S | Common Stock | 5873 | $86.53 | 84,024.0000 | 22,322,000 | 6.53% | 0.03% |
| Aug. 12, 2025 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | S | Common Stock | 4975 | $85.71 | 40,794.0000 | 22,322,000 | 10.87% | 0.02% |
| July 18, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 2071 | $66.30 | 76,874.0000 | 22,322,000 | 2.62% | 0.01% |
| July 14, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $64.88 | 78,945.0000 | 22,322,000 | 0.50% | 0.00% |
| June 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $61.37 | 79,345.0000 | 21,538,000 | 0.50% | 0.00% |
| May 22, 2025 | Pera Antonio R | Director | A | Common Stock | 4336 | $0.00 | 35,373.0000 | 21,538,000 | 13.97% | 0.02% |
| May 22, 2025 | TANNENBAUM RENEE P | Director | A | Common Stock | 4336 | $0.00 | 26,957.0000 | 21,538,000 | 19.17% | 0.02% |
| May 22, 2025 | Walsh Patrick D | Director | A | Common Stock | 4336 | $0.00 | 79,048.0000 | 21,538,000 | 5.80% | 0.02% |
| May 22, 2025 | Thoma Jeanne | Director | A | Common Stock | 4336 | $0.00 | 44,945.0000 | 21,538,000 | 10.68% | 0.02% |
| May 22, 2025 | HAUGHEY THOMAS | Director | A | Common Stock | 4336 | $0.00 | 55,862.0000 | 21,538,000 | 8.42% | 0.02% |
| May 22, 2025 | Leonard Matthew J | Director | A | Common Stock | 4336 | $0.00 | 16,329.0000 | 21,538,000 | 36.15% | 0.02% |
| May 15, 2025 | Gutwerg Ori | SVP, GENERICS | S | Common Stock | 881 | $60.07 | 89,897.0000 | 21,538,000 | 0.97% | 0.00% |
| May 14, 2025 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 4000 | $60.45 | 107,317.0000 | 21,538,000 | 3.59% | 0.02% |
| May 9, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 700 | $76.83 | 729,508.0000 | 21,538,000 | 0.10% | 0.00% |
| May 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $62.20 | 79,745.0000 | 21,538,000 | 0.50% | 0.00% |
| April 14, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $68.96 | 80,145.0000 | 21,538,000 | 0.50% | 0.00% |
| March 23, 2025 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 6210 | $64.26 | 180,863.0000 | 21,538,000 | 3.32% | 0.03% |
| March 23, 2025 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 17455 | $64.26 | 468,179.0000 | 21,538,000 | 3.59% | 0.08% |
| March 19, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 1866 | $65.00 | 64,659.0000 | 21,538,000 | 2.80% | 0.01% |
| March 7, 2025 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 2874 | $60.62 | 111,317.0000 | 21,538,000 | 2.52% | 0.01% |
| March 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $63.33 | 80,545.0000 | 21,538,000 | 0.49% | 0.00% |
| March 7, 2025 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 17060 | $60.62 | 485,634.0000 | 21,538,000 | 3.39% | 0.08% |
| March 7, 2025 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 3314 | $60.62 | 90,778.0000 | 21,538,000 | 3.52% | 0.02% |
| March 7, 2025 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 5150 | $60.62 | 187,073.0000 | 21,538,000 | 2.68% | 0.02% |
| March 7, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 1000 | $60.86 | 66,525.0000 | 21,538,000 | 1.48% | 0.00% |
| March 5, 2025 | Gutwerg Ori | SVP, GENERICS | M | Common Stock | 300 | $31.49 | 99,476.0000 | 21,538,000 | 0.30% | 0.00% |
| March 5, 2025 | Gutwerg Ori | SVP, GENERICS | S | Common Stock | 300 | $60.03 | 99,176.0000 | 21,538,000 | 0.30% | 0.00% |
| March 5, 2025 | Gutwerg Ori | SVP, GENERICS | S | Common Stock | 5084 | $60.00 | 94,092.0000 | 21,538,000 | 5.13% | 0.02% |
| March 5, 2025 | Gutwerg Ori | SVP, GENERICS | M | Stock Option (right to buy) | 300 | $31.49 | 13,204.0000 | 21,538,000 | 2.22% | 0.00% |
| Feb. 28, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 1099 | $61.89 | 67,525.0000 | 21,538,000 | 1.60% | 0.01% |
| Feb. 28, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 1099 | $61.89 | 80,945.0000 | 21,538,000 | 1.34% | 0.01% |
| Feb. 28, 2025 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 1861 | $61.89 | 192,223.0000 | 21,538,000 | 0.96% | 0.01% |
| Feb. 28, 2025 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F | Common Stock | 627 | $61.89 | 45,465.0000 | 21,538,000 | 1.36% | 0.00% |
| Feb. 28, 2025 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 1275 | $61.89 | 114,191.0000 | 21,538,000 | 1.10% | 0.01% |
| Feb. 28, 2025 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 12216 | $61.89 | 502,694.0000 | 21,538,000 | 2.37% | 0.06% |
| Feb. 28, 2025 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 1570 | $61.89 | 99,176.0000 | 21,538,000 | 1.56% | 0.01% |
| Feb. 21, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 1000 | $60.20 | 68,624.0000 | 21,538,000 | 1.44% | 0.00% |
| Feb. 14, 2025 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F | Common Stock | 582 | $58.92 | 46,092.0000 | 21,538,000 | 1.25% | 0.00% |
| Feb. 12, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | A | Common Stock | 14362 | $0.00 | 720,634.0000 | 21,538,000 | 2.03% | 0.07% |
| Feb. 12, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | A | Common Stock | 9574 | $0.00 | 730,208.0000 | 21,538,000 | 1.33% | 0.04% |
| Feb. 12, 2025 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | A | Common Stock | 7834 | $0.00 | 41,452.0000 | 21,538,000 | 23.30% | 0.04% |
| Feb. 12, 2025 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | A | Common Stock | 5222 | $0.00 | 46,674.0000 | 21,538,000 | 12.60% | 0.02% |
| Feb. 12, 2025 | Mutz Christopher | HEAD OF RARE DISEASE | A | Common Stock | 24808 | $0.00 | 101,585.0000 | 21,538,000 | 32.31% | 0.12% |
| Feb. 12, 2025 | Mutz Christopher | HEAD OF RARE DISEASE | A | Common Stock | 16538 | $0.00 | 118,123.0000 | 21,538,000 | 16.28% | 0.08% |
| Feb. 14, 2025 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 1473 | $58.92 | 116,650.0000 | 21,538,000 | 1.25% | 0.01% |
| Feb. 15, 2025 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 1184 | $58.92 | 115,466.0000 | 21,538,000 | 1.02% | 0.01% |
| Feb. 12, 2025 | Lalwani Nikhil | PRESIDENT & CEO | A | Common Stock | 91399 | $0.00 | 461,777.0000 | 21,538,000 | 24.68% | 0.42% |
| Feb. 12, 2025 | Lalwani Nikhil | PRESIDENT & CEO | A | Common Stock | 60932 | $0.00 | 522,709.0000 | 21,538,000 | 13.20% | 0.28% |
| Feb. 14, 2025 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 7799 | $58.92 | 514,910.0000 | 21,538,000 | 1.49% | 0.04% |
| Feb. 12, 2025 | Gutwerg Ori | SVP, GENERICS | A | Common Stock | 15668 | $0.00 | 92,895.0000 | 21,538,000 | 20.29% | 0.07% |
| Feb. 12, 2025 | Gutwerg Ori | SVP, GENERICS | A | Common Stock | 10444 | $0.00 | 103,339.0000 | 21,538,000 | 11.24% | 0.05% |
| Feb. 14, 2025 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 1426 | $58.92 | 101,913.0000 | 21,538,000 | 1.38% | 0.01% |
| Feb. 15, 2025 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 1167 | $58.92 | 100,746.0000 | 21,538,000 | 1.15% | 0.01% |
| Feb. 12, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | A | Common Stock | 14362 | $0.00 | 257,267.0000 | 21,538,000 | 5.91% | 0.07% |
| Feb. 12, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | A | Common Stock | 9574 | $0.00 | 266,841.0000 | 21,538,000 | 3.72% | 0.04% |
| Feb. 12, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | A | Common Stock | 13057 | $0.00 | 62,116.0000 | 21,538,000 | 26.61% | 0.06% |
| Feb. 12, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | A | Common Stock | 8704 | $0.00 | 70,820.0000 | 21,538,000 | 14.01% | 0.04% |
| Feb. 14, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 1196 | $58.92 | 69,624.0000 | 21,538,000 | 1.69% | 0.01% |
| Feb. 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | A | Common Stock | 16974 | $0.00 | 72,562.0000 | 21,538,000 | 30.54% | 0.08% |
| Feb. 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | A | Common Stock | 11316 | $0.00 | 83,878.0000 | 21,538,000 | 15.59% | 0.05% |
| Feb. 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $59.54 | 83,478.0000 | 21,538,000 | 0.48% | 0.00% |
| Feb. 14, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 1434 | $58.92 | 82,044.0000 | 21,538,000 | 1.72% | 0.01% |
| Feb. 12, 2025 | CAREY STEPHEN P. | SVP & CFO | A | Common Stock | 24808 | $0.00 | 179,276.0000 | 21,538,000 | 16.06% | 0.12% |
| Feb. 12, 2025 | CAREY STEPHEN P. | SVP & CFO | A | Common Stock | 16538 | $0.00 | 195,814.0000 | 21,538,000 | 9.22% | 0.08% |
| Feb. 14, 2025 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 1730 | $58.92 | 194,084.0000 | 21,538,000 | 0.88% | 0.01% |
| Jan. 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 400 | $53.92 | 55,588.0000 | 21,538,000 | 0.71% | 0.00% |
| Dec. 17, 2024 | CAREY STEPHEN P. | SVP & CFO | S | Common Stock | 7500 | $55.79 | 154,468.0000 | 21,494,000 | 4.63% | 0.03% |
| Dec. 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $56.24 | 55,988.0000 | 21,494,000 | 0.44% | 0.00% |
| Dec. 11, 2024 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 1000 | $60.00 | 49,059.0000 | 21,494,000 | 2.00% | 0.00% |
| Nov. 26, 2024 | Lalwani Nikhil | PRESIDENT & CEO | S | Common Stock | 3481 | $58.30 | 370,378.0000 | 21,494,000 | 0.93% | 0.02% |
| Nov. 26, 2024 | Lalwani Nikhil | PRESIDENT & CEO | M | Common Stock | 30000 | $29.00 | 403,859.0000 | 21,494,000 | 8.02% | 0.14% |
| Nov. 26, 2024 | Lalwani Nikhil | PRESIDENT & CEO | S | Common Stock | 30000 | $57.95 | 373,859.0000 | 21,494,000 | 7.43% | 0.14% |
| Nov. 26, 2024 | Lalwani Nikhil | PRESIDENT & CEO | M | Stock Option (right to buy) | 30000 | $29.00 | 138,027.0000 | 21,494,000 | 17.85% | 0.14% |
| Nov. 15, 2024 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F | Common Stock | 867 | $56.58 | 33,169.0000 | 21,494,000 | 2.55% | 0.00% |
| Nov. 15, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 6500 | $57.70 | 76,777.0000 | 21,494,000 | 7.81% | 0.03% |
| Nov. 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $61.36 | 56,238.0000 | 21,494,000 | 0.44% | 0.00% |
| Oct. 14, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $57.19 | 56,488.0000 | 21,494,000 | 0.44% | 0.00% |
| Sept. 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $56.82 | 56,738.0000 | 21,476,000 | 0.44% | 0.00% |
| Sept. 12, 2024 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 1486 | $56.15 | 50,059.0000 | 21,476,000 | 2.88% | 0.01% |
| Sept. 8, 2024 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 3646 | $60.51 | 373,859.0000 | 21,476,000 | 0.97% | 0.02% |
| Aug. 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $59.62 | 56,988.0000 | 21,476,000 | 0.44% | 0.00% |
| July 18, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 1743 | $61.35 | 57,238.0000 | 21,476,000 | 2.96% | 0.01% |
| July 18, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 2743 | $62.00 | 706,272.0000 | 21,476,000 | 0.39% | 0.01% |
| July 16, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 22000 | $64.27 | 723,272.0000 | 21,476,000 | 2.95% | 0.10% |
| July 17, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 14257 | $63.16 | 709,015.0000 | 21,476,000 | 1.97% | 0.07% |
| July 15, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 11000 | $63.38 | 745,272.0000 | 21,476,000 | 1.45% | 0.05% |
| July 12, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $64.91 | 58,981.0000 | 21,476,000 | 0.42% | 0.00% |
| July 1, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $63.44 | 242,905.0000 | 21,476,000 | 7.61% | 0.09% |
| June 21, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 20000 | $58.90 | 756,272.0000 | 20,731,000 | 2.58% | 0.10% |
| June 18, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 10607 | $60.76 | 787,719.0000 | 20,731,000 | 1.33% | 0.05% |
| June 20, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 11447 | $59.86 | 776,272.0000 | 20,731,000 | 1.45% | 0.06% |
| June 17, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 7946 | $61.41 | 798,326.0000 | 20,731,000 | 0.99% | 0.04% |
| June 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $63.80 | 59,231.0000 | 20,731,000 | 0.42% | 0.00% |
| June 7, 2024 | Marken James G. | SVP OPS & PROD DEV | M | Stock Option (right to buy) | 5300 | $57.06 | 0.0000 | 20,731,000 | 100.00% | 0.03% |
| June 7, 2024 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 11087 | $67.70 | 117,829.0000 | 20,731,000 | 8.60% | 0.05% |
| June 7, 2024 | Marken James G. | SVP OPS & PROD DEV | M | Stock Option (right to buy) | 7250 | $49.51 | 0.0000 | 20,731,000 | 100.00% | 0.03% |
| June 7, 2024 | Marken James G. | SVP OPS & PROD DEV | M | Common Stock | 7250 | $49.51 | 123,616.0000 | 20,731,000 | 6.23% | 0.03% |
| June 7, 2024 | Marken James G. | SVP OPS & PROD DEV | M | Common Stock | 5300 | $57.06 | 128,916.0000 | 20,731,000 | 4.29% | 0.03% |
| June 4, 2024 | CAREY STEPHEN P. | SVP & CFO | S | Common Stock | 5000 | $63.58 | 161,968.0000 | 20,731,000 | 2.99% | 0.02% |
| June 5, 2024 | Gutwerg Ori | SVP, GENERICS | S | Common Stock | 2985 | $67.00 | 77,227.0000 | 20,731,000 | 3.72% | 0.01% |
| June 3, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $64.41 | 262,905.0000 | 20,731,000 | 7.07% | 0.10% |
| May 21, 2024 | TANNENBAUM RENEE P | Director | A | Common Stock | 4410 | $0.00 | 22,621.0000 | 20,731,000 | 24.22% | 0.02% |
| May 21, 2024 | Walsh Patrick D | Director | A | Common Stock | 4410 | $0.00 | 74,712.0000 | 20,731,000 | 6.27% | 0.02% |
| May 21, 2024 | Pera Antonio R | Director | A | Common Stock | 4410 | $0.00 | 31,037.0000 | 20,731,000 | 16.56% | 0.02% |
| May 21, 2024 | Thoma Jeanne | Director | A | Common Stock | 4410 | $0.00 | 40,609.0000 | 20,731,000 | 12.18% | 0.02% |
| May 21, 2024 | HAUGHEY THOMAS | Director | A | Common Stock | 4410 | $0.00 | 51,526.0000 | 20,731,000 | 9.36% | 0.02% |
| May 21, 2024 | Leonard Matthew J | Director | A | Common Stock | 4410 | $0.00 | 11,993.0000 | 20,731,000 | 58.16% | 0.02% |
| May 21, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 2000 | $61.61 | 83,277.0000 | 20,731,000 | 2.35% | 0.01% |
| May 20, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 12855 | $61.81 | 806,272.0000 | 20,731,000 | 1.57% | 0.06% |
| May 15, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 14850 | $65.86 | 841,422.0000 | 20,731,000 | 1.73% | 0.07% |
| May 16, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 16459 | $63.84 | 824,963.0000 | 20,731,000 | 1.96% | 0.08% |
| May 17, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 5836 | $62.09 | 819,127.0000 | 20,731,000 | 0.71% | 0.03% |
| May 16, 2024 | TANNENBAUM RENEE P | Director | S | Common Stock | 2000 | $63.87 | 18,211.0000 | 20,731,000 | 9.90% | 0.01% |
| May 14, 2024 | Lalwani Nikhil | PRESIDENT & CEO | S | Common Stock | 16669 | $66.10 | 377,505.0000 | 20,731,000 | 4.23% | 0.08% |
| May 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $67.69 | 59,481.0000 | 20,731,000 | 0.42% | 0.00% |
| May 1, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $66.62 | 282,905.0000 | 20,731,000 | 6.60% | 0.10% |
| April 18, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 10423 | $64.98 | 873,081.0000 | 20,731,000 | 1.18% | 0.05% |
| April 19, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 16809 | $65.17 | 856,272.0000 | 20,731,000 | 1.93% | 0.08% |
| April 15, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 7414 | $66.33 | 898,858.0000 | 20,731,000 | 0.82% | 0.04% |
| April 16, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 5834 | $66.20 | 893,024.0000 | 20,731,000 | 0.65% | 0.03% |
| April 17, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 9520 | $65.40 | 883,504.0000 | 20,731,000 | 1.07% | 0.05% |
| April 12, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $67.79 | 59,731.0000 | 20,731,000 | 0.42% | 0.00% |
| April 10, 2024 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 4534 | $66.96 | 166,968.0000 | 20,731,000 | 2.64% | 0.02% |
| April 10, 2024 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 2799 | $66.96 | 116,006.0000 | 20,731,000 | 2.36% | 0.01% |
| April 1, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $67.25 | 302,905.0000 | 20,731,000 | 6.19% | 0.10% |
| March 23, 2024 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 6210 | $69.58 | 171,502.0000 | 20,731,000 | 3.49% | 0.03% |
| March 23, 2024 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 3653 | $69.58 | 118,805.0000 | 20,731,000 | 2.98% | 0.02% |
| March 23, 2024 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 17455 | $69.58 | 394,174.0000 | 20,731,000 | 4.24% | 0.08% |
| March 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $66.54 | 59,981.0000 | 20,731,000 | 0.42% | 0.00% |
| March 11, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $65.81 | 322,905.0000 | 20,731,000 | 5.83% | 0.10% |
| March 8, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 10000 | $67.17 | 906,272.0000 | 20,731,000 | 1.09% | 0.05% |
| March 7, 2024 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 4216 | $66.71 | 185,499.0000 | 20,731,000 | 2.22% | 0.02% |
| March 11, 2024 | CAREY STEPHEN P. | SVP & CFO | S | Common Stock | 7787 | $65.55 | 177,712.0000 | 20,731,000 | 4.20% | 0.04% |
| March 6, 2024 | Lalwani Nikhil | PRESIDENT & CEO | S | Common Stock | 28965 | $65.52 | 444,981.0000 | 20,731,000 | 6.11% | 0.14% |
| March 7, 2024 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 17060 | $66.71 | 427,921.0000 | 20,731,000 | 3.83% | 0.08% |
| March 8, 2024 | Lalwani Nikhil | PRESIDENT & CEO | S | Common Stock | 16292 | $67.13 | 411,629.0000 | 20,731,000 | 3.81% | 0.08% |
| March 7, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 15085 | $66.35 | 916,272.0000 | 20,731,000 | 1.62% | 0.07% |
| March 7, 2024 | Marken James G. | SVP OPS & PROD DEV | S | Common Stock | 24338 | $66.37 | 124,492.0000 | 20,731,000 | 16.35% | 0.12% |
| March 7, 2024 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 2034 | $66.71 | 122,458.0000 | 20,731,000 | 1.63% | 0.01% |
| March 7, 2024 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 2494 | $66.71 | 80,212.0000 | 20,731,000 | 3.02% | 0.01% |
| March 7, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 2110 | $66.71 | 85,277.0000 | 20,731,000 | 2.41% | 0.01% |
| March 5, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 10093 | $65.35 | 946,179.0000 | 20,731,000 | 1.06% | 0.05% |
| March 6, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 14822 | $65.47 | 931,357.0000 | 20,731,000 | 1.57% | 0.07% |
| March 4, 2024 | Pera Antonio R | Director | S | Common Stock | 7000 | $65.20 | 26,627.0000 | 20,731,000 | 20.82% | 0.03% |
| March 5, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 5000 | $66.00 | 87,387.0000 | 20,731,000 | 5.41% | 0.02% |
| Feb. 29, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 1275 | $67.67 | 92,387.0000 | 20,731,000 | 1.36% | 0.01% |
| Feb. 29, 2024 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 1914 | $67.67 | 189,715.0000 | 20,731,000 | 1.00% | 0.01% |
| Feb. 29, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 1173 | $67.67 | 60,231.0000 | 20,731,000 | 1.91% | 0.01% |
| Feb. 29, 2024 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 1173 | $67.67 | 51,545.0000 | 20,731,000 | 2.23% | 0.01% |
| Feb. 29, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | F | Common Stock | 1635 | $67.67 | 342,905.0000 | 20,731,000 | 0.47% | 0.01% |
| Feb. 29, 2024 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 1570 | $67.67 | 82,706.0000 | 20,731,000 | 1.86% | 0.01% |
| Feb. 29, 2024 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 10014 | $67.67 | 473,946.0000 | 20,731,000 | 2.07% | 0.05% |
| Feb. 29, 2024 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 1058 | $67.67 | 148,830.0000 | 20,731,000 | 0.71% | 0.01% |
| Feb. 29, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | F | Common Stock | 1122 | $67.67 | 956,272.0000 | 20,731,000 | 0.12% | 0.01% |
| Feb. 15, 2024 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 1244 | $57.55 | 84,276.0000 | 20,731,000 | 1.45% | 0.01% |
| Feb. 15, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 1261 | $57.55 | 93,662.0000 | 20,731,000 | 1.33% | 0.01% |
| Feb. 14, 2024 | Lalwani Nikhil | PRESIDENT & CEO | A | Common Stock | 80530 | $0.00 | 430,274.0000 | 20,731,000 | 23.03% | 0.39% |
| Feb. 14, 2024 | Lalwani Nikhil | PRESIDENT & CEO | A | Common Stock | 53686 | $0.00 | 483,960.0000 | 20,731,000 | 12.48% | 0.26% |
| Feb. 14, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | A | Common Stock | 13421 | $0.00 | 948,448.0000 | 20,731,000 | 1.44% | 0.06% |
| Feb. 14, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | A | Common Stock | 8946 | $0.00 | 957,394.0000 | 20,731,000 | 0.94% | 0.04% |
| Feb. 14, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | A | Common Stock | 18790 | $0.00 | 82,397.0000 | 20,731,000 | 29.54% | 0.09% |
| Feb. 14, 2024 | Mutz Christopher | HEAD OF RARE DISEASE | A | Common Stock | 12526 | $0.00 | 94,923.0000 | 20,731,000 | 15.20% | 0.06% |
| Feb. 14, 2024 | Marken James G. | SVP OPS & PROD DEV | A | Common Stock | 10066 | $0.00 | 143,178.0000 | 20,731,000 | 7.56% | 0.05% |
| Feb. 14, 2024 | Marken James G. | SVP OPS & PROD DEV | A | Common Stock | 6710 | $0.00 | 149,888.0000 | 20,731,000 | 4.69% | 0.03% |
| Feb. 14, 2024 | Gutwerg Ori | SVP, GENERICS | A | Common Stock | 14763 | $0.00 | 75,678.0000 | 20,731,000 | 24.24% | 0.07% |
| Feb. 14, 2024 | Gutwerg Ori | SVP, GENERICS | A | Common Stock | 9842 | $0.00 | 85,520.0000 | 20,731,000 | 13.01% | 0.05% |
| Feb. 14, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | A | Common Stock | 13421 | $0.00 | 335,594.0000 | 20,731,000 | 4.17% | 0.06% |
| Feb. 14, 2024 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | A | Common Stock | 8946 | $0.00 | 344,540.0000 | 20,731,000 | 2.67% | 0.04% |
| Feb. 14, 2024 | Davis Krista | SVP, CHIEF HR OFFICER | A | Common Stock | 12079 | $0.00 | 44,666.0000 | 20,731,000 | 37.07% | 0.06% |
| Feb. 14, 2024 | Davis Krista | SVP, CHIEF HR OFFICER | A | Common Stock | 8052 | $0.00 | 52,718.0000 | 20,731,000 | 18.03% | 0.04% |
| Feb. 14, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | A | Common Stock | 14763 | $0.00 | 51,562.0000 | 20,731,000 | 40.12% | 0.07% |
| Feb. 14, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | A | Common Stock | 9842 | $0.00 | 61,404.0000 | 20,731,000 | 19.09% | 0.05% |
| Feb. 14, 2024 | CAREY STEPHEN P. | SVP & CFO | A | Common Stock | 21474 | $0.00 | 177,313.0000 | 20,731,000 | 13.78% | 0.10% |
| Feb. 14, 2024 | CAREY STEPHEN P. | SVP & CFO | A | Common Stock | 14316 | $0.00 | 191,629.0000 | 20,731,000 | 8.07% | 0.07% |
| Feb. 13, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $56.04 | 36,799.0000 | 20,731,000 | 0.67% | 0.00% |
| Jan. 19, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 4524 | $55.57 | 955,719.0000 | 20,731,000 | 0.47% | 0.02% |
| Jan. 22, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 5692 | $55.95 | 950,027.0000 | 20,731,000 | 0.60% | 0.03% |
| Jan. 23, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 15000 | $56.44 | 935,027.0000 | 20,731,000 | 1.58% | 0.07% |
| Jan. 17, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 10000 | $55.11 | 970,027.0000 | 20,731,000 | 1.02% | 0.05% |
| Jan. 16, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 5000 | $55.63 | 980,027.0000 | 20,731,000 | 0.51% | 0.02% |
| Jan. 18, 2024 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 9784 | $55.30 | 960,243.0000 | 20,731,000 | 1.01% | 0.05% |
| Jan. 12, 2024 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $56.43 | 37,049.0000 | 20,731,000 | 0.67% | 0.00% |
| Dec. 15, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 11974 | $52.44 | 1,023,053.0000 | 17,644,000 | 1.16% | 0.07% |
| Dec. 19, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 25000 | $52.65 | 985,027.0000 | 17,644,000 | 2.48% | 0.14% |
| Dec. 18, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 13026 | $52.44 | 1,010,027.0000 | 17,644,000 | 1.27% | 0.07% |
| Dec. 11, 2023 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $49.21 | 37,299.0000 | 17,644,000 | 0.67% | 0.00% |
| Nov. 15, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 7647 | $53.64 | 1,002,068.0000 | 17,644,000 | 0.76% | 0.04% |
| Nov. 16, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 6448 | $51.66 | 995,620.0000 | 17,644,000 | 0.64% | 0.04% |
| Nov. 17, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 13000 | $51.00 | 1,035,027.0000 | 17,644,000 | 1.24% | 0.07% |
| Nov. 14, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 22905 | $53.17 | 1,009,715.0000 | 17,644,000 | 2.22% | 0.13% |
| Nov. 16, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 6448 | $51.66 | 1,048,837.0000 | 17,644,000 | 0.61% | 0.04% |
| Nov. 15, 2023 | Davis Krista | SVP, CHIEF HR OFFICER | S | Common Stock | 2622 | $53.81 | 32,587.0000 | 17,644,000 | 7.45% | 0.01% |
| Nov. 14, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 22095 | $53.17 | 1,062,932.0000 | 17,644,000 | 2.04% | 0.13% |
| Nov. 15, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 7647 | $53.64 | 1,055,285.0000 | 17,644,000 | 0.72% | 0.04% |
| Nov. 13, 2023 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | S | Common Stock | 250 | $52.03 | 37,549.0000 | 17,644,000 | 0.66% | 0.00% |
| Nov. 10, 2023 | Mutz Christopher | HEAD OF RARE DISEASE | S | Common Stock | 3000 | $52.47 | 63,607.0000 | 17,644,000 | 4.50% | 0.02% |
| Oct. 18, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 6242 | $57.78 | 1,095,027.0000 | 17,644,000 | 0.57% | 0.04% |
| Oct. 19, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 10000 | $57.06 | 1,085,027.0000 | 17,644,000 | 0.91% | 0.06% |
| Oct. 17, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 8758 | $58.53 | 1,101,269.0000 | 17,644,000 | 0.79% | 0.05% |
| Oct. 13, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 11937 | $57.58 | 1,123,090.0000 | 17,644,000 | 1.05% | 0.07% |
| Oct. 16, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 13063 | $58.31 | 1,110,027.0000 | 17,644,000 | 1.16% | 0.07% |
| Oct. 2, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $56.48 | 322,173.0000 | 17,644,000 | 5.84% | 0.11% |
| Sept. 15, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 16242 | $62.81 | 1,168,785.0000 | 17,644,000 | 1.37% | 0.09% |
| Sept. 18, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 8425 | $61.64 | 1,160,360.0000 | 17,644,000 | 0.72% | 0.05% |
| Sept. 19, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 25333 | $61.23 | 1,135,027.0000 | 17,644,000 | 2.18% | 0.14% |
| Sept. 12, 2023 | Davis Krista | SVP, CHIEF HR OFFICER | F | Common Stock | 1486 | $61.91 | 35,209.0000 | 17,644,000 | 4.05% | 0.01% |
| Sept. 8, 2023 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 3646 | $61.94 | 349,744.0000 | 17,644,000 | 1.03% | 0.02% |
| Sept. 1, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $64.70 | 342,173.0000 | 17,644,000 | 5.52% | 0.11% |
| Aug. 28, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 25000 | $63.06 | 1,210,027.0000 | 17,644,000 | 2.02% | 0.14% |
| Aug. 29, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 25000 | $63.37 | 1,185,027.0000 | 17,644,000 | 2.07% | 0.14% |
| Aug. 23, 2023 | Marken James G. | SVP OPS & PROD DEV | M | Common Stock | 3750 | $40.59 | 135,377.0000 | 17,644,000 | 2.85% | 0.02% |
| Aug. 23, 2023 | Gutwerg Ori | SVP, GENERICS | M | Common Stock | 13502 | $31.49 | 76,476.0000 | 17,644,000 | 21.44% | 0.08% |
| Aug. 23, 2023 | Gutwerg Ori | SVP, GENERICS | S | Common Stock | 13502 | $62.39 | 62,974.0000 | 17,644,000 | 17.66% | 0.08% |
| Aug. 23, 2023 | Gutwerg Ori | SVP, GENERICS | S | Common Stock | 2059 | $62.39 | 60,915.0000 | 17,644,000 | 3.27% | 0.01% |
| Aug. 23, 2023 | Gutwerg Ori | SVP, GENERICS | M | Stock Option (right to buy) | 13502 | $31.49 | 13,504.0000 | 17,644,000 | 50.00% | 0.08% |
| Aug. 23, 2023 | Marken James G. | SVP OPS & PROD DEV | M | Common Stock | 1667 | $33.00 | 137,044.0000 | 17,644,000 | 1.23% | 0.01% |
| Aug. 23, 2023 | Marken James G. | SVP OPS & PROD DEV | S | Common Stock | 3932 | $63.00 | 133,112.0000 | 17,644,000 | 2.87% | 0.02% |
| Aug. 23, 2023 | Marken James G. | SVP OPS & PROD DEV | M | Stock Option (right to buy) | 3750 | $40.59 | 0.0000 | 17,644,000 | 100.00% | 0.02% |
| Aug. 23, 2023 | Marken James G. | SVP OPS & PROD DEV | M | Stock Option (right to buy) | 1667 | $33.00 | 0.0000 | 17,644,000 | 100.00% | 0.01% |
| Aug. 21, 2023 | Leonard Matthew J | Director | A | Common Stock | 7583 | $0.00 | 7,583.0000 | 17,644,000 | 9999.99% | 0.04% |
| Aug. 14, 2023 | CAREY STEPHEN P. | SVP & CFO | S | Common Stock | 17639 | $61.37 | 155,839.0000 | 17,644,000 | 10.17% | 0.10% |
| Aug. 16, 2023 | MERIDIAN VENTURE PARTNERS II LP | TenPercentOwner | S | Common Stock | 200000 | $58.50 | 1,819,259.0000 | 17,644,000 | 9.90% | 1.13% |
| Aug. 14, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 27890 | $61.15 | 1,257,137.0000 | 17,644,000 | 2.17% | 0.16% |
| Aug. 15, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 22110 | $61.60 | 1,235,027.0000 | 17,644,000 | 1.76% | 0.13% |
| Aug. 15, 2023 | Lalwani Nikhil | PRESIDENT & CEO | M | Common Stock | 11616 | $29.00 | 365,006.0000 | 17,644,000 | 3.29% | 0.07% |
| Aug. 15, 2023 | Lalwani Nikhil | PRESIDENT & CEO | M | Stock Option (right to buy) | 11616 | $29.00 | 168,027.0000 | 17,644,000 | 6.47% | 0.07% |
| Aug. 14, 2023 | Pera Antonio R | Director | S | Common Stock | 3000 | $60.37 | 33,627.0000 | 17,644,000 | 8.19% | 0.02% |
| Aug. 11, 2023 | Lalwani Nikhil | PRESIDENT & CEO | S | Common Stock | 56666 | $57.75 | 353,390.0000 | 17,644,000 | 13.82% | 0.32% |
| Aug. 15, 2023 | Lalwani Nikhil | PRESIDENT & CEO | S | Common Stock | 11616 | $61.13 | 353,390.0000 | 17,644,000 | 3.18% | 0.07% |
| Aug. 1, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $51.06 | 362,173.0000 | 17,644,000 | 5.23% | 0.11% |
| July 19, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 5969 | $51.48 | 1,302,527.0000 | 17,644,000 | 0.46% | 0.03% |
| July 21, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 11500 | $52.56 | 1,285,027.0000 | 17,644,000 | 0.89% | 0.07% |
| July 20, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 6000 | $51.52 | 1,296,527.0000 | 17,644,000 | 0.46% | 0.03% |
| July 18, 2023 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | Common Stock | 1743 | $51.89 | 37,799.0000 | 17,644,000 | 4.41% | 0.01% |
| July 18, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 6700 | $51.84 | 1,308,496.0000 | 17,644,000 | 0.51% | 0.04% |
| July 14, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 10000 | $50.43 | 1,325,027.0000 | 17,644,000 | 0.75% | 0.06% |
| July 17, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 9831 | $51.06 | 1,315,196.0000 | 17,644,000 | 0.74% | 0.06% |
| July 3, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $53.43 | 382,173.0000 | 17,644,000 | 4.97% | 0.11% |
| June 23, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 10000 | $51.49 | 1,335,027.0000 | 17,644,000 | 0.74% | 0.06% |
| June 20, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 14657 | $51.93 | 1,370,370.0000 | 17,644,000 | 1.06% | 0.08% |
| June 22, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | S | Common Stock | 20000 | $51.32 | 402,173.0000 | 17,644,000 | 4.74% | 0.11% |
| June 21, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 11843 | $51.95 | 1,358,527.0000 | 17,644,000 | 0.86% | 0.07% |
| June 22, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 13500 | $51.38 | 1,345,027.0000 | 17,644,000 | 0.99% | 0.08% |
| June 22, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 13500 | $51.38 | 1,345,027.0000 | 17,644,000 | 0.99% | 0.08% |
| June 20, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 14657 | $51.93 | 1,370,370.0000 | 17,644,000 | 1.06% | 0.08% |
| June 21, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | S | Common Stock | 11843 | $51.95 | 1,358,527.0000 | 17,644,000 | 0.86% | 0.07% |
| May 23, 2023 | TANNENBAUM RENEE P | Director | A | Common Stock | 6865 | $0.00 | 20,211.0000 | 17,644,000 | 51.44% | 0.04% |
| May 23, 2023 | Walsh Patrick D | Director | A | Common Stock | 6865 | $0.00 | 70,302.0000 | 17,644,000 | 10.82% | 0.04% |
| May 23, 2023 | Thoma Jeanne | Director | A | Common Stock | 6865 | $0.00 | 36,199.0000 | 17,644,000 | 23.40% | 0.04% |
| May 23, 2023 | Pera Antonio R | Director | A | Common Stock | 6865 | $0.00 | 36,627.0000 | 17,644,000 | 23.07% | 0.04% |
| May 23, 2023 | HAUGHEY THOMAS | Director | A | Common Stock | 6865 | $0.00 | 47,116.0000 | 17,644,000 | 17.06% | 0.04% |
| May 23, 2023 | NASH DAVID | Director | A | Common Stock | 6865 | $0.00 | 38,561.0000 | 17,644,000 | 21.66% | 0.04% |
| April 10, 2023 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 2289 | $38.50 | 131,627.0000 | 17,644,000 | 1.71% | 0.01% |
| April 10, 2023 | CAREY STEPHEN P. | SVP & CFO | F | Common Stock | 4534 | $38.50 | 173,478.0000 | 17,644,000 | 2.55% | 0.03% |
| Feb. 28, 2023 | CAREY STEPHEN P. | SVP & CFO | A | Common Stock | 24316 | $0.00 | 161,802.0000 | 17,644,000 | 17.69% | 0.14% |
| Feb. 28, 2023 | CAREY STEPHEN P. | SVP & CFO | A | Common Stock | 16210 | $0.00 | 178,012.0000 | 17,644,000 | 10.02% | 0.09% |
| Feb. 28, 2023 | Lalwani Nikhil | PRESIDENT & CEO | A | Common Stock | 63686 | $0.00 | 410,056.0000 | 17,644,000 | 18.39% | 0.36% |
| Feb. 28, 2023 | Lalwani Nikhil | PRESIDENT & CEO | A | Common Stock | 95530 | $0.00 | 346,370.0000 | 17,644,000 | 38.08% | 0.54% |
| Feb. 28, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | A | Common Stock | 17369 | $0.00 | 1,373,449.0000 | 17,644,000 | 1.28% | 0.10% |
| Feb. 28, 2023 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | A | Common Stock | 11578 | $0.00 | 1,385,027.0000 | 17,644,000 | 0.84% | 0.07% |
| Feb. 28, 2023 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | A | Common Stock | 8104 | $0.00 | 39,542.0000 | 17,644,000 | 25.78% | 0.05% |
| Feb. 28, 2023 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | A | Common Stock | 12158 | $0.00 | 31,438.0000 | 17,644,000 | 63.06% | 0.07% |
| Feb. 28, 2023 | Davis Krista | SVP, CHIEF HR OFFICER | A | Common Stock | 8104 | $0.00 | 36,695.0000 | 17,644,000 | 28.34% | 0.05% |
| Feb. 28, 2023 | Davis Krista | SVP, CHIEF HR OFFICER | A | Common Stock | 12158 | $0.00 | 28,591.0000 | 17,644,000 | 73.99% | 0.07% |
| Feb. 28, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | A | Common Stock | 11578 | $0.00 | 422,173.0000 | 17,644,000 | 2.82% | 0.07% |
| Feb. 28, 2023 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | A | Common Stock | 17369 | $0.00 | 410,595.0000 | 17,644,000 | 4.42% | 0.10% |
| Feb. 28, 2023 | Gutwerg Ori | SVP, GENERICS | A | Common Stock | 11578 | $0.00 | 62,974.0000 | 17,644,000 | 22.53% | 0.07% |
| Feb. 28, 2023 | Gutwerg Ori | SVP, GENERICS | A | Common Stock | 17369 | $0.00 | 51,396.0000 | 17,644,000 | 51.04% | 0.10% |
| Feb. 28, 2023 | Marken James G. | SVP OPS & PROD DEV | A | Common Stock | 8684 | $0.00 | 133,916.0000 | 17,644,000 | 6.93% | 0.05% |
| Feb. 28, 2023 | Marken James G. | SVP OPS & PROD DEV | A | Common Stock | 13026 | $0.00 | 125,232.0000 | 17,644,000 | 11.61% | 0.07% |
| Feb. 28, 2023 | Mutz Christopher | HEAD OF RARE DISEASE | A | Common Stock | 11578 | $0.00 | 66,607.0000 | 17,644,000 | 21.04% | 0.07% |
| Feb. 28, 2023 | Mutz Christopher | HEAD OF RARE DISEASE | A | Common Stock | 17369 | $0.00 | 55,029.0000 | 17,644,000 | 46.12% | 0.10% |
| March 28, 2023 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 524 | $38.62 | 112,206.0000 | 17,644,000 | 0.46% | 0.00% |
| March 28, 2023 | CAREY STEPHEN P. | SVP AND CFO | F | Common Stock | 1420 | $38.62 | 137,486.0000 | 17,644,000 | 1.02% | 0.01% |
| March 23, 2023 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 17455 | $37.82 | 250,840.0000 | 17,644,000 | 6.51% | 0.10% |
| March 23, 2023 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 2452 | $37.82 | 112,730.0000 | 17,644,000 | 2.13% | 0.01% |
| March 23, 2023 | CAREY STEPHEN P. | SVP AND CFO | F | Common Stock | 4224 | $37.82 | 138,906.0000 | 17,644,000 | 2.95% | 0.02% |
| March 7, 2023 | CAREY STEPHEN P. | SVP AND CFO | F | Common Stock | 864 | $44.23 | 143,130.0000 | 17,644,000 | 0.60% | 0.00% |
| March 7, 2023 | CAREY STEPHEN P. | SVP AND CFO | F | Common Stock | 2639 | $44.23 | 143,994.0000 | 17,644,000 | 1.80% | 0.01% |
| March 7, 2023 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 586 | $44.23 | 34,027.0000 | 17,644,000 | 1.69% | 0.00% |
| March 7, 2023 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 1756 | $44.23 | 34,613.0000 | 17,644,000 | 4.83% | 0.01% |
| March 7, 2023 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 476 | $44.23 | 37,660.0000 | 17,644,000 | 1.25% | 0.00% |
| March 7, 2023 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 1426 | $44.23 | 38,136.0000 | 17,644,000 | 3.60% | 0.01% |
| March 7, 2023 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 509 | $44.23 | 115,182.0000 | 17,644,000 | 0.44% | 0.00% |
| March 7, 2023 | Marken James G. | SVP OPS & PROD DEV | F | Common Stock | 1951 | $44.23 | 115,691.0000 | 17,644,000 | 1.66% | 0.01% |
| March 7, 2023 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 9397 | $44.23 | 272,560.0000 | 17,644,000 | 3.33% | 0.05% |
| March 7, 2023 | Lalwani Nikhil | PRESIDENT & CEO | F | Common Stock | 4265 | $44.23 | 268,295.0000 | 17,644,000 | 1.56% | 0.02% |
| Feb. 15, 2023 | Mutz Christopher | HEAD OF RARE DISEASE | F | Common Stock | 1292 | $45.04 | 39,562.0000 | 17,644,000 | 3.16% | 0.01% |
| Feb. 15, 2023 | Gutwerg Ori | SVP, GENERICS | F | Common Stock | 1275 | $45.04 | 36,369.0000 | 17,644,000 | 3.39% | 0.01% |